SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
Allogene Therapeutics: Q3 Earnings Snapshot
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),...
Allogene Therapeutics received a Sell rating and price target from J.P. Morgan analyst Brian Cheng today. The company’s shares closed yesterday at $1.27.Elevate Your Investing Strategy: Take advantage...
In a report released today, Brian Cheng from J.P. Morgan maintained a Sell rating on Allogene Therapeutics. The company’s shares closed yesterday at $1.51.Elevate Your Investing Strategy: Take advantage...
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
Allogene Therapeutics ALLO incurred a second-quarter 2025 loss of 23 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 28 cents. In the year-ago period, the company had...
Allogene Therapeutics: Q2 Earnings Snapshot